NICE Implementation Collaborative (NIC)
The NIC is a unique partnership between the NHS, Life Sciences industry, Healthcare professional bodies, key health organisations and Patient groups. NIC partners are committed to working together to support a system where patients have faster and more consistent access to NICE-recommended medicines, treatments and technologies and is a collaboration which completely re-draws the landscape. Industry will now work with academia, clinical groups, NHS England, NICE and representative bodies to drive compliance with NICE recommendations.
The partnership underpinned by the signing of a concordat in March 2013. The Concordat is made up of the following members:
- Academy of Medical Royal Colleges
- Association of British Healthcare Industries (ABHI)
- Foundation Trust Network
- NHS Alliance NHS
- Commissioning Assembly
- NHS Confederation
- NHS England
- National Institute for Health and Care Excellence (NICE)
- Patients Involved in NICE
- Royal Pharmaceutical Society
- The Academy of Medical Sciences
- The Association of the British Pharmaceutical Industry (ABPI)
- The British In Vitro Diagnostics Association (BIVDA)
What does the NIC do?
- Identify practical measures that support and promote timely and consistent implementation of NICE Technology Appraisals throughout the NHS in England
- Work jointly to support and promote the adoption of all other forms of NICE guidance that apply to the NHS in England, and to drive the uptake of innovation, in a way that is consistent with local health needs and priorities
- Understand the barriers that restrict expected levels of implementation and uptake, including the requirement for CCGs to provide care for their populations taking into account local affordability and clinical need. The NIC will identify practical measures that its members and all organisations providing NHS services to patients can take to help overcome these barriers
- Support a culture shift within the NHS in favour of clinically- and cost-effective innovation
|Latest NIC work streams|
|Recent NIC work streams|
Novel Oral Anti-coagulants (NOAC's)
|NICE Technology Appraisal guidance 249, 256 and the draft guidance for apixaban deal with the novel oral anticoagulants dabigatran etexilate and rivaroxaban and their use to prevent stroke and and systemic embolism in people with atrial fibrillation. Stroke is the third largest cause of death in England and costs the NHS £2.8 billion each year. Atrial Fibrillation (AF) is a known risk factor for stroke, increasing its risk and severity.|
Over the last few years novel oral anticoagulants (NOACs) have become available, and in the last 12 months three have been recommended by NICE as cost effective for prevention of stroke in people living with AF, meaning that here are now effective choices for patients and healthcare professionals beyond the established use of warfarin.
What are the barriers to uptake of NICE guidance?
The NIC has worked with the system to better understand the barriers that exist to the use of novel oral anticoagulants. These include:
To address many of these barriers the NIC launched a NIC NOAC Consensus Statement on the 18th of June 2014. Click on the link to find out more and download the document.
More information on the current uptale of NOACs can be found in the most recent Innovation Scorecard publication
|Relevant NIC documents|